ClinicalTrials.gg
Status unknownNCT05971771Updated Aug 2, 2023

Study to Assess Impact of Dietary Supplement on Sleep Health

An interventional study of Placebo and Treatment in Sleep, sponsored by Pharmanex. Status unknown. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-02.

Sponsored by Pharmanex (part of Nu Skin Enterprises) · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Sleep is essential for health and wellness. Sleep disruption can occur due to emotional stress, advancing age, hormonal imbalance, medications, and many other causes, some of which are presently unknown. Most pharmaceutical sleep products artificially induce sedation without providing quality sleep. Thus, a need exists for safe dietary supplement to promote and support healthy sleep that will encourage restful sleep. This study will examine the efficacy, tolerance, and safety of sleep supplement as compared to a placebo.

02

Conditions studied

  • Sleep

Keywords

  • Sleep
  • Alertness
  • Restfulness
  • Dietary AND Supplement
03

In context

Lead sponsor

Pharmanex is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

First submitted after Pharmanex became part of Nu Skin Enterprises.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is male or female 20-60 years of age at the time of informed consent.
  • Recorded baseline BMI is ≥18.5 and ≤29.9 kg/m2.
  • A score of 5 or higher on the Pittsburgh Sleep Quality Index.
  • Willing and able to give informed consent
  • Willing to maintain consistent diet and physical activity through the study period.
  • Willing to limit alcohol consumption to ≤14 drinks per week, no more than 4 drinks at a time, and no more than 1 drink within 4h of bedtime.
  • Willing to limit caffeine consumption to no more than 4 servings per day and no caffeine within 6h of bedtime.

Exclusion criteria

Exclusion Criteria:

  • Could not or did not want to participate in clinical study.
  • Taken nutritional supplements for sleep or stress in the previous 6 months.
  • Have received non-pharmacological treatment for sleep disorders (eg. Cognitive behavioral therapy, relation therapy) in previous 6 months
  • Any known allergy or intolerance to any of the ingredients contained in supplement.
  • Planned surgical procedure during the course of the study.
  • Used nicotine in the past 6 months.
  • Have a major psychiatric disorder as determined by the Mini International Neuropsychiatric Inventory
  • A history of unconventional sleep pattern, a diagnosed sleep disorder, or chronic medical condition that could affect energy/fatigue levels.
  • Consume more than 400mg of caffeine per day in the past 2 weeks.
  • Used any psychotropic medications, stimulants, cannabis, non-registered drug products, or illicit substances in the past 4 weeks.
  • At risk of drug or alcohol abuse
  • Used any sleep aids in the past 2 weeks.
  • Employed in night shift work or rotational shift work
  • Currently pregnant, nursing, planning to become pregnant, or unwilling to use a medically approved form of contraception will be excluded.
  • Individuals who sleep more than 10 hours.
  • Typically take a nap during the day.
  • Those planning travel or vacation during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active: Sleep Supplement containing Magnesium and Saffron Extract

    Powder that is to be mixed into 3oz. of water, 30-60 minutes before going to bed

    Dietary Supplement: Treatment

  • Placebo comparator
    Placebo

    Placebo that is 2 softgels that will be taken with water, 30-60 minutes prior to going to bed.

    Other: Placebo

Interventions

  • OtherPlacebo

    Two softgels to be taken with water that is to be consumed approximately 30-60 minutes before going to bed

    Also known as: Placebo Supplement

  • Dietary supplementTreatment

    14mg saffron extract and 250mg magnesium citrate that is powder that is mixed in 3-4 oz of water and consumed 30-60 minutes before going to bed

    Also known as: Supplement for supporting sleep

06

What researchers measure

Primary outcomes

  1. Change from baseline sleep quality index

    Change from baseline in validated Pittsburgh Sleep Quality Index (0-21, higher number indicates poorer quality)

    Time frame: Baseline, Day 1, Day 7, Day 28

  2. Change from baseline sleep duration and quality from diary

    Change from baseline with Daily Sleep Diary

    Time frame: Baseline and Daily for 28 days

Secondary outcomes

  1. Change from baseline perceived stress scale

    Change from baseline with validated perceived stress questionnaire

    Time frame: Baseline, Day 1, Day 7, Day 28

  2. Change from baseline Insomnia severity index

    Change from baseline using validated Insomnia Severity Index (0-28, higher number indicates more severe insomnia)

    Time frame: Baseline, Day 1, Day 7, Day 28

  3. Change from baseline in restorative sleep as measured by Restorative Sleep Questionnaire (RSQ)

    Change from baseline using restorative sleep questionnaire as measured by Restorative Sleep Questionnaire (RSQ) that is a 9-item scale/question assessing symptoms over the last week. The total score ranges from 0 to 100, with higher scores indicating better restorative sleep

    Time frame: Baseline, Day 1, Day 7, Day 28

  4. Change from baseline in mood

    Change from baseline using abbreviated Profile of Mood States (POMS) is a widely used questionnaire of 24 items and four scales. Total numbers range from 0-not at all to 4-very strong

    Time frame: Baseline, Day 1, Day 7, Day 28

  5. Change from baseline in skin attributes

    Change from baseline in skin attributes using 1-5 scale (1 strongly disagree to 5 strongly agree) with questionnaire regarding skin appearance (youthfulness, glow, evenness, hydration, etc)

    Time frame: Baseline, Day 7, and Day 28

Other outcomes

  1. Change in diastolic blood pressure measurement (safety measure)

    Change from baseline diastolic blood pressure changes using sphygmomanometer

    Time frame: Baseline and Day 28

  2. Change in systolic blood pressure measurement (safety measure)

    Change from baseline systolic blood pressure changes using sphygmomanometer

    Time frame: Baseline and Day 28

  3. Change in body weight

    change from baseline in body weight as measured in pounds

    Time frame: Baseline and Day Day 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05971771
Lead sponsor
Pharmanex
Collaborators
Dermatology Consulting Services, High Point NC
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Aug 1, 2023 (estimated)
Primary completion
Aug 30, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Aug 2, 2023

Study contacts

Zoe D Diana, MD
Contact
zdraelos@northstate.net
336-841-2040

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion